Nuvectis Pharma Inc (NVCT)

$23.99 +1.50 (6.67%)
Market Cap 783.13M
Revenue (ttm) 0.00
Net Income (ttm) -26.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 221,000
Avg Vol 238,604
Day's Range N/A - N/A
Shares Out 32.64M
Stochastic %K 62%
Beta -0.26
Analysts Strong Sell
Price Target $35.50

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States
UNLV
UNLV Sep. 11 at 5:58 PM
$NVCT fireside chat ultra impressive. CEO explained Novartis trial expanding indications Fabhalta which correlates with opportunity to expand indications lead drug NXP100. No talk around NXP900 mono therapies. Small cash strapped company moving largest market opportunities forward Much bigger opportunities than when I was buying $6 shares. NXP100 oral once daily, lifetime
0 · Reply
UNLV
UNLV Sep. 3 at 1:58 PM
$NVCT Company doing Fireside chat Sept 11, Conference presentation Sept 14 I’m completely in the dark around “real world” data updates company promised NXP900 open label trial. Stock 4x since last year and I told everyone don’t wait on data with INSIDER BUYING going ballistic. Is ASTRAZENECA buying, takeover?
0 · Reply
WallStWireAds
WallStWireAds Sep. 3 at 12:07 PM
$NVCT https://www.globenewswire.com/news-release/2026/09/03/3355841/0/en/nuvectis-pharma-to-participate-in-upcoming-investor-conferences.ht
0 · Reply
UNLV
UNLV Sep. 2 at 6:30 PM
$GLSI added $15+ …reduced $NVCT $23+ Still own more NVCT but just had to swap some. GLSI the cheaper stock and the bigger near term catalyst
0 · Reply
bbear0731
bbear0731 Aug. 27 at 11:03 PM
$NVCT What's with ALL the Activity in the Oct $NVCT calls lately??? Last few days.......Unusual for $NVCT, imo,,,,
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:25 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!!!!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $NVCT $ORMP $BGDE $WW
0 · Reply
bbear0731
bbear0731 Aug. 25 at 9:24 PM
$NVCT I think NVCT is IN PLAY for a takeover.....I heard rumors of Amgen and Astrezeneca(?).....Love to see a BIDDING WAR!
2 · Reply
bbear0731
bbear0731 Aug. 25 at 9:23 PM
$NVCT
0 · Reply
UNLV
UNLV Aug. 25 at 4:53 PM
$NVCT is AstraZeneca buying NVCT stock? I’ve speculated partnership around Tagrisso combo but buyout wins a totality. Nuvectis could have downplayed mono therapies letting AstraZeneca buy stock on the cheap. AstraZeneca marketing clout would really strengthen licensing deal. AstraZeneca, Nuvectis and licensing partner Haisco might be on to something. 2027 bring it on
0 · Reply
STACKD0E
STACKD0E Aug. 25 at 4:47 PM
$NVCT 🙃 ✨️
0 · Reply
Latest News on NVCT
Nuvectis Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2026, 9:10 AM EDT - 2 days ago

Nuvectis Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Nuvectis Pharma Slides: Corporate presentation

Sep 11, 2026, 7:00 AM EDT - 2 days ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Sep 3, 2026, 8:00 AM EDT - 10 days ago

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

2026-08-24T11:15:53.000Z - 20 days ago

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

2026-08-24T10:25:20.000Z - 20 days ago

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

Nuvectis Pharma files $200M mixed securities shelf

2026-08-21T20:40:09.000Z - 22 days ago

Nuvectis Pharma files $200M mixed securities shelf

Nuvectis Pharma Registration statement: Registration filing

Aug 21, 2026, 8:00 AM EDT - 23 days ago

Nuvectis Pharma Registration statement: Registration filing

Nuvectis Pharma Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 4 weeks ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital

2026-08-05T10:11:18.000Z - 5 weeks ago

Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital

Nuvectis Pharma Earnings release: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Nuvectis Pharma Earnings release: Q2 2026

Nuvectis Pharma Quarterly report: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 5 weeks ago

Nuvectis Pharma Quarterly report: Q2 2026

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Jul 23, 2026, 9:00 AM EDT - 7 weeks ago

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma receives marketing approval in China for ciprocopan

2026-07-23T11:45:23.000Z - 7 weeks ago

Nuvectis Pharma receives marketing approval in China for ciprocopan

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Jul 23, 2026, 7:30 AM EDT - 7 weeks ago

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Jul 14, 2026, 10:40 AM EDT - 2 months ago

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

2026-07-06T01:00:06.000Z - 2 months ago

Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

Nuvectis Pharma 5M share Spot Secondary priced at $20.00

2026-06-30T10:10:10.000Z - 2 months ago

Nuvectis Pharma 5M share Spot Secondary priced at $20.00

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Jun 29, 2026, 10:30 PM EDT - 2 months ago

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

2026-06-29T21:50:11.000Z - 2 months ago

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

Nuvectis Pharma announces common stock offering, no amount given

2026-06-29T20:05:18.000Z - 2 months ago

Nuvectis Pharma announces common stock offering, no amount given

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Jun 29, 2026, 4:01 PM EDT - 2 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

2026-06-22T17:42:15.000Z - 2 months ago

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

2026-06-22T15:06:27.000Z - 2 months ago

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Jun 22, 2026, 8:34 AM EDT - 2 months ago

Nuvectis gains two experimental drugs in licensing deal with China's Haisco

Nuvectis Pharma Transcript: Status update

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Nuvectis Pharma Transcript: Status update

Nuvectis Pharma Press release: Status update

Jun 22, 2026, 8:30 AM EDT - 2 months ago

Nuvectis Pharma Press release: Status update

Nuvectis Pharma announces license agreement with Haisco for two compounds

2026-06-22T12:01:43.000Z - 2 months ago

Nuvectis Pharma announces license agreement with Haisco for two compounds

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Jun 22, 2026, 7:30 AM EDT - 2 months ago

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

2026-06-12T16:12:33.000Z - 3 months ago

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

Nuvectis Pharma Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 3 months ago

Nuvectis Pharma Transcript: AGM 2026

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 9:00 AM EDT - 3 months ago

Nuvectis Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 14, 2026, 7:30 AM EDT - 4 months ago

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Nuvectis Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 4 months ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026, 7:30 AM EDT - 4 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 4 months ago

Nuvectis Pharma Earnings release: Q1 2026

Nuvectis Pharma Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 4 months ago

Nuvectis Pharma Quarterly report: Q1 2026

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Nuvectis Pharma Proxy statement: Proxy filing

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma management to meet with Maxim

2026-03-19T19:35:17.000Z - 5 months ago

Nuvectis Pharma management to meet with Maxim

Nuvectis Pharma Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 6 months ago

Nuvectis Pharma Slides: Corporate presentation

Nuvectis Pharma files $150M mixed securities shelf

2026-02-13T21:05:11.000Z - 7 months ago

Nuvectis Pharma files $150M mixed securities shelf

Nuvectis Pharma Registration statement: Registration Filing

Feb 13, 2026, 7:00 AM EST - 7 months ago

Nuvectis Pharma Registration statement: Registration Filing

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Feb 11, 2026, 7:30 AM EST - 7 months ago

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2025

Feb 11, 2026, 7:00 AM EST - 7 months ago

Nuvectis Pharma Earnings release: Q4 2025

Nuvectis Pharma Annual report: Q4 2025

Feb 11, 2026, 7:00 AM EST - 7 months ago

Nuvectis Pharma Annual report: Q4 2025

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

2025-12-17T12:13:26.000Z - 9 months ago

Nuvectis Pharma announces initiation of Phase 1b study of NXP900

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Dec 17, 2025, 7:00 AM EST - 9 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma Transcript: KOL Event

Dec 2, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma Transcript: KOL Event

Nuvectis Pharma Slides: KOL Event

Dec 2, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma Slides: KOL Event

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 25, 2025, 8:00 AM EST - 9 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nuvectis Pharma Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Nuvectis Pharma Earnings release: Q3 2025

Nuvectis Pharma Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 10 months ago

Nuvectis Pharma Quarterly report: Q3 2025

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

2025-11-04T13:20:44.000Z - 10 months ago

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 8:15 AM EST - 10 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

2025-11-04T12:36:25.000Z - 10 months ago

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2025, 8:00 AM EDT - 11 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nuvectis Pharma Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Nuvectis Pharma Transcript: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma Press release: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Press release: Status Update

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Nuvectis Pharma Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q2 2025

Nuvectis Pharma Earnings release: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q2 2025

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Jul 31, 2025, 7:45 AM EDT - 1 year ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

Nuvectis Pharma Slides: Corporate Presentation

Jun 13, 2025, 11:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 10:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2025, 4:35 PM EDT - 1 year ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q1 2025

Nuvectis Pharma Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q1 2025

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

May 6, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Apr 29, 2025, 4:25 PM EDT - 1 year ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Nuvectis Pharma Annual report: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Annual report: Q4 2024

Nuvectis Pharma Earnings release: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q4 2024

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Quarterly report: Q3 2024

Nuvectis Pharma Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q3 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 12:00 PM EDT - 2 years ago

Nuvectis Pharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Nuvectis Pharma Quarterly report: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q2 2024

Nuvectis Pharma Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q2 2024

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 6, 2024, 8:28 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q1 2024

Nuvectis Pharma Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q1 2024

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing

Nuvectis Pharma Slides: Corporate Presentation

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Slides: Corporate Presentation

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Nuvectis Pharma Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q4 2023

Nuvectis Pharma Annual report: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Annual report: Q4 2023

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Quarterly report: Q3 2023

Nuvectis Pharma Earnings release: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q3 2023

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Nuvectis Pharma Transcript: Status Update

Sep 14, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Transcript: Status Update

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 9, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

Nuvectis Pharma Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q2 2023

Nuvectis Pharma Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q2 2023

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

UNLV
UNLV Sep. 11 at 5:58 PM
$NVCT fireside chat ultra impressive. CEO explained Novartis trial expanding indications Fabhalta which correlates with opportunity to expand indications lead drug NXP100. No talk around NXP900 mono therapies. Small cash strapped company moving largest market opportunities forward Much bigger opportunities than when I was buying $6 shares. NXP100 oral once daily, lifetime
0 · Reply
UNLV
UNLV Sep. 3 at 1:58 PM
$NVCT Company doing Fireside chat Sept 11, Conference presentation Sept 14 I’m completely in the dark around “real world” data updates company promised NXP900 open label trial. Stock 4x since last year and I told everyone don’t wait on data with INSIDER BUYING going ballistic. Is ASTRAZENECA buying, takeover?
0 · Reply
WallStWireAds
WallStWireAds Sep. 3 at 12:07 PM
$NVCT https://www.globenewswire.com/news-release/2026/09/03/3355841/0/en/nuvectis-pharma-to-participate-in-upcoming-investor-conferences.ht
0 · Reply
UNLV
UNLV Sep. 2 at 6:30 PM
$GLSI added $15+ …reduced $NVCT $23+ Still own more NVCT but just had to swap some. GLSI the cheaper stock and the bigger near term catalyst
0 · Reply
bbear0731
bbear0731 Aug. 27 at 11:03 PM
$NVCT What's with ALL the Activity in the Oct $NVCT calls lately??? Last few days.......Unusual for $NVCT, imo,,,,
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 26 at 4:25 AM
$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!!!!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $NVCT $ORMP $BGDE $WW
0 · Reply
bbear0731
bbear0731 Aug. 25 at 9:24 PM
$NVCT I think NVCT is IN PLAY for a takeover.....I heard rumors of Amgen and Astrezeneca(?).....Love to see a BIDDING WAR!
2 · Reply
bbear0731
bbear0731 Aug. 25 at 9:23 PM
$NVCT
0 · Reply
UNLV
UNLV Aug. 25 at 4:53 PM
$NVCT is AstraZeneca buying NVCT stock? I’ve speculated partnership around Tagrisso combo but buyout wins a totality. Nuvectis could have downplayed mono therapies letting AstraZeneca buy stock on the cheap. AstraZeneca marketing clout would really strengthen licensing deal. AstraZeneca, Nuvectis and licensing partner Haisco might be on to something. 2027 bring it on
0 · Reply
STACKD0E
STACKD0E Aug. 25 at 4:47 PM
$NVCT 🙃 ✨️
0 · Reply
UNLV
UNLV Aug. 25 at 3:25 PM
$NVCT up 400% and I’m telling you traders on “StockTwits and X” really botched this trade GLSI around insider activity a big trade
0 · Reply
STACKD0E
STACKD0E Aug. 24 at 7:25 PM
$NVCT 🙃 ✨️
0 · Reply
focafoca99
focafoca99 Aug. 21 at 8:42 PM
$NVCT has launched a new at-the-market offering with Jefferies, replacing its prior ATM program.
0 · Reply
UNLV
UNLV Aug. 20 at 9:55 AM
$NVCT $23 insider Charles Mosseri Marlio up 4x on ALL-IN investment since last year I continually referenced insider trading “StockTwits and X” because it’s number 1 tool for successfully trading small caps. Confidently move into huge positions at ground floor levels Charles hasn’t sold, we’re going higher
0 · Reply
bbear0731
bbear0731 Aug. 19 at 7:31 PM
$NVCT Something is cooking at $ NVCT.....Is one of the Big Boys making a move to buy $NVCT?
0 · Reply
UNLV
UNLV Aug. 19 at 3:46 PM
$NVCT $22 what becomes of the faint hearted? I wonder if faint hearted screwed up AI trades as badly botched NVCT trades were here. Think about that, I believe AI trades were botched tiny gains Insiders still deep NVCT GLSI haven’t sold a single share…WHAT ARE YOU DOING?
3 · Reply
UNLV
UNLV Aug. 17 at 1:30 PM
$NVCT last year’s lows had Charles loading, loading and reloading $5, $6, $7 and $8 shares. WHAT WERE YOU DOING? Charles was going all-in and I was tailing Charles GLSI $16 and now after last year’s debacle waiting on data you can join insider buying, my number 1 tool. Sold a fraction of NVCT to join this dance
0 · Reply
UNLV
UNLV Aug. 15 at 3:11 PM
$NVCT All you need to successfully trade small cap stocks are INSIDER TRADING tools, that’s it. End of story as other info comes in as NICE TO KNOW. Looking forward NVCT $100 remembering NXP900 trials expanding resistance and the multi billion dollar drug partners will have patients waiting without needs of huge sales teams that start off slow. MASSIVE PORTFOLIO POSITION
0 · Reply
UNLV
UNLV Aug. 15 at 2:55 PM
$NVCT just as I liked NVCT around insider buying also like $GLSI around insider buying. Sold small fraction of NVCT up 3x for me, to buy GLSI. Insider trading my NUMBER 1 indicator with small caps…everything changes, everything is connected PAY ATTENTION phase 3 drug and 250M market cap
2 · Reply
UNLV
UNLV Aug. 14 at 4:07 PM
$NVCT 600M market cap and best in class drug NXP100 in what’s expected to become 10B market. NXP200 looking best in class with only seeming downside paying royalties. NXP100 resistance combo as well but faint of heart, was faint of heart at lows $5, $6, $7…Sold a fraction to join insider buying of 200M market cap “GLSI”
0 · Reply
UNLV
UNLV Aug. 14 at 1:17 PM
$NVCT noise and chatter from faint of heart but I’m saying stock has superior prospects for 600M market cap Out of strength sold fraction of NVCT buying $GLSI 200M market cap alongside CEO buying GLSI = OVERWEIGHT NVCT = HUGE OVERWEIGHT Make your moves out of STRENGTH not out of weakness, moves out of weakness are always bad
0 · Reply
BioTrade2
BioTrade2 Aug. 14 at 10:46 AM
$NVCT look at the latest company presentation, total slides 24, nxp900 slides: 2 (buried at the end). You would think they would be eager to show upcoming data. Same thing happened last year when they got rid of the 800 program.
1 · Reply